证券代码：002773 证券简称：康弘药业 公告编号：2023-065 成都康弘药业集团股份有限公司 关于对子公司实施增资暨关联交易的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称 "公司"）于2023 年7月12日召开的第七届董事会第二十次会议和2023年8月3日召开的 二〇二三年第一次临时股东大会审议通过了《关于对子公司实施增 资的议案》，为进一步支持基因疗法开发业务开展、实现公司战略 规划，同时充分调动公司及子公司经营管理团队、核心骨干的积极 性，促进与公司的共同成长，公司与员工持股平台成都康济企业管 理咨询合伙企业（有限合伙）、成都康因企业管理咨询合伙企业 （有限合伙）及成都康至科技咨询合伙企业（有限合伙）拟对公司 控股子公司成都弘基生物科技有限公司（以下简称"弘基生物"） 以货币方式实施增资，拟合计增资15,973.6344万元。本次增资完成 后，弘基生物注册资本将增加至31,973.6344万元，其中成都康弘药 业集团股份有限公司认缴出资27,800.0000万元，占比86.95%；成都 康济企业管 ...

证券代码： 002773 证券简称：康弘药业 成都康弘药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------------|--------------------------------------------------------| | 投资者关系活动 | □特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 √ | 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | | 人员姓名 | | | | 时间 | 2023 年 5 月 22 日 ( | 周一) 下午 15:00~17:00 | | 地点 | | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待人 | 1、董事长柯尊洪 | | | 员姓名 | 2、董事、总裁柯潇 | | | | ...

成都康弘药业集团股份有限公司 关于举行二○二二年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 成都康弘药业集团股份有限公司（以下简称"公司"）《二○二 二年度报告及摘要》已经公司第七届董事会第十九次会议审议通过， 相关信息详见2023年4月28日公司指定信息披露媒体《证券时报》、 《中国证券报》、《上海证券报》、《证券日报》及巨潮资讯网 （www.cninfo.com.cn）。 证券代码：002773 证券简称：康弘药业 公告编号：2023-026 为便于广大投资者进一步了解公司《二○二二年度报告》内容及 二○二二年度生产经营情况，公司将于2023年5月22日（星期一）下 午15：00 至17：00在全景网举办二○二二年度业绩说明会，本次年 度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明 会。 出席本次年度业绩说明会的人员有：公司董事长柯尊洪先生，董 事总裁柯潇先生，董事副总裁殷劲群先生，独立董事张强先生、屈三 才先生、张宇先生，副总裁、财务总监 ...

Financial Performance - The company's net profit for the reporting period was CNY 71,132,923.09, a decrease from CNY 120,472,548.79 in the previous period, reflecting a significant decline of 41.0%[5]. - The total revenue for 2022 was CNY 388,035,167.96, representing a year-on-year increase of 9.43% compared to CNY 354,605,557.16 in 2021[26]. - The company achieved operating revenue of CNY 338,902.82 million, a year-on-year decrease of 6.00%[183]. - The net profit attributable to shareholders was CNY 89,667.00 million, representing a year-on-year increase of 112.94%[183]. - The total distributable profit for the reporting period was 3,508,590,344.36 RMB[128]. Research and Development - The company reported a net cash flow from operating activities that increased by 87.23% year-on-year, primarily due to reduced R&D expenses related to the cessation of a global clinical trial[33]. - The number of R&D personnel decreased by 5.06% to 507, with the proportion of R&D staff in total employees dropping to 12.53% from 13.88%[31]. - Research and development (R&D) investment amounted to CNY 435,006,851.08, a decrease of 57.71% compared to the previous year[186]. - R&D investment as a percentage of operating revenue was 12.84%, down 15.69% from the previous year[186]. - The company capitalized CNY 61,009,243.44 of R&D expenses, an increase of 199.51% year-on-year[186]. - The company plans to gradually advance research work on multiple products that have received clinical trial permits from the National Medical Products Administration[21]. - The company emphasizes its core competitiveness in innovation, focusing on unmet clinical needs and the development of high-tech new products[129]. Expenses and Financial Management - The sales expenses decreased by 5.94% to CNY 1,320,234,211.04 from CNY 1,403,622,206.56 in the previous year[29]. - The company’s financial expenses decreased by 30.92% to CNY -44,944,155.32, mainly due to increased interest income from time deposits[29]. - The company’s investment income from financial products amounted to CNY 37,394,399.95, indicating a focus on enhancing daily fund management and efficiency[5]. Stock Options and Incentives - The company granted 120,000 stock options to 2 incentive objects on July 11, 2022, with an exercise price of 14.97 CNY per share, accounting for 3.76% of the reserved stock options and 0.0131% of the total share capital on the announcement date[40]. - The first exercise period conditions for the 2021 stock option incentive plan were met, allowing 326 incentive objects to exercise a total of 3.8588 million stock options at an exercise price of 22.18 CNY per share[41]. - A total of 1.8892 million stock options were canceled for 102 incentive objects due to reasons such as resignation or not meeting performance targets[41]. - The company has implemented a stock appreciation rights incentive plan, granting a total of 600,000 shares, representing 0.07% of the total share capital[93]. - The company approved the grant of 600,000 stock appreciation rights to one incentive object as part of its 2022 stock appreciation rights incentive plan[169]. Corporate Governance and Compliance - The company has established a comprehensive performance evaluation system for its directors, supervisors, and senior management, linking compensation to company performance and individual achievements[123]. - The company is committed to improving internal control systems and governance structures in compliance with relevant laws and regulations[192]. - The internal control self-assessment report reflects that the company has no significant or important internal control deficiencies during the reporting period[198]. - The report provides a comprehensive, truthful, and accurate reflection of the company's internal control situation[200]. Market and Strategic Initiatives - The company aims to improve its marketing strategies and rapidly capture market share in relevant fields[106]. - The company has formed a product layout advantage in the treatment of chronic diseases such as hypertension and diabetes, as well as common diseases in respiratory and digestive departments, and major diseases in ophthalmology and neurology[158]. - The company has undergone a merger, with Sichuan Hongda Pharmaceutical Co., Ltd. being absorbed by Sichuan Hongyuan Pharmaceutical Co., Ltd., which continues to operate[103]. - The company faces potential changes in product access conditions and sales prices due to ongoing healthcare reforms and intensified industry competition, which may impact sales[107]. - The company has conducted thorough feasibility studies for its fundraising projects, but future market uncertainties pose risks of not meeting expected revenue and profit targets[108]. Investments and Projects - The total procurement amount from the top five suppliers was 68,187,569.85 CNY, representing 24.93% of the annual total procurement[55]. - The procurement amount from the first supplier was 16,855,233.52 CNY, accounting for 6.16% of the annual total procurement[55]. - The total amount of committed investment for the project of solid oral preparations is CNY 296.59 million, with an adjusted total investment of CNY 251.31 million, achieving an investment progress of 92.24%[68]. - The R&D center expansion project has a total committed investment of CNY 175.87 million, with a cumulative investment of CNY 181.92 million, indicating an investment progress of 103.44%[68]. - The marketing service network construction project has a total committed investment of CNY 75.84 million, with a cumulative investment of CNY 11.17 million, achieving 100% of the expected benefits[68]. - The KH series biopharmaceutical industrialization project has a total committed investment of CNY 50 million, with a cumulative investment of CNY 50.85 million, achieving an investment progress of 101.70%[68]. Employee Development - The company is committed to continuous employee training, utilizing various platforms and methods to enhance skills and capabilities across all levels[124]. - The company has established a unique human resource management model and culture, focusing on talent acquisition and development in R&D, production, and sales[159]. Dividends and Shareholder Meetings - The company distributed a cash dividend of 1.50 RMB per 10 shares, totaling 137,919,593.10 RMB, which represents 100% of the distributable profit[128]. - The total number of shares for the dividend distribution was 919,463,954 shares[128]. - The company held two shareholders' meetings, five board meetings, and five supervisory board meetings during the reporting period[192].

Financial Performance - Total revenue for Q1 2023 was CNY 88,483.86 million, a decrease of 1.16% compared to CNY 89,521.23 million in Q1 2022[3] - The revenue from traditional Chinese medicine reached CNY 33,680.52 million, representing a 10.72% increase year-over-year[3] - The revenue from chemical drugs decreased by 17.06% to CNY 20,398.74 million compared to CNY 24,594.54 million in the same period last year[3] - The company reported a net profit of CNY 12,799,852.71 from non-operating income and expenses after tax adjustments[4] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.30, down from CNY 0.32 in the previous year[14] - Net profit attributable to shareholders of the listed company was ¥279,331,041.04, down 6.03% from ¥297,240,188.25 year-on-year[54] - The net profit after deducting non-recurring gains and losses was ¥266,531,188.33, a decrease of 4.63% from ¥279,472,064.65 year-on-year[54] Cash Flow and Assets - Cash and cash equivalents decreased by 40.38% to CNY 2,137,765,906.48 from CNY 3,585,368,804.77 at the beginning of the year[5] - The net cash flow from operating activities is CNY 187,686,073.46, down from CNY 288,758,045.97 in the previous period[31] - The net cash flow from operating activities decreased by 35.00%, amounting to ¥187,686,073.46 compared to ¥288,758,045.97 in the previous year[54] - The cash and cash equivalents at the end of the period amount to CNY 2,122,513,089.46, compared to CNY 1,914,464,515.05 in the previous period[32] - The company’s total assets at the end of the period are CNY 7,897,627,039.38, an increase from CNY 7,720,729,941.31[28] - The total assets at the end of the reporting period were ¥7,897,627,039.38, reflecting a 2.29% increase from ¥7,720,729,941.31 at the end of the previous year[54] Liabilities and Equity - The company's total liabilities amount to CNY 713,323,012.95, a decrease from CNY 813,851,345.77 in the previous period[28] - The total non-current liabilities are CNY 106,638,444.55, down from CNY 120,191,379.00[28] - The equity attributable to shareholders of the listed company increased by 4.05% to ¥7,181,367,694.78 from ¥6,901,806,830.70[54] - The total equity attributable to the parent company is CNY 7,181,367,694.78, up from CNY 6,901,806,830.70 in the previous period[28] Research and Development - R&D expenses for Q1 2023 were CNY 68,663,415.81, up from CNY 54,727,925.74 in Q1 2022, reflecting a focus on innovation[12] Government Support - The company received government subsidies amounting to CNY 16,229,962.73, contributing to its financial performance[4] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47,320, with the largest shareholder holding 31.76% of shares[24] Other Financial Metrics - The weighted average return on net assets was 3.97%, down from 4.76% in the previous year[54] Changes in Receivables and Payables - Accounts receivable rose by 46.57% to CNY 219,305,112.58, indicating an increase in outstanding payments[5] - Other receivables increased by 71.58% compared to the beginning of the period, mainly due to an increase in the reserve fund during the reporting period[57] - Prepayments increased by 209.48% compared to the beginning of the period, primarily due to an increase in sales discount refunds during the reporting period[57] - Employee compensation payable decreased by 61.82% compared to the beginning of the period, mainly due to the payment of last year's year-end bonuses during the reporting period[57] - Taxes payable increased by 90.66% compared to the beginning of the period, primarily due to an increase in corporate income tax payable during the reporting period[57] - Other payables increased by 66.56% compared to the beginning of the period, mainly due to an increase in payable expense reimbursements during the reporting period[57] - Other current liabilities decreased by 49.35% compared to the beginning of the period, mainly due to a decrease in estimated discounts during the reporting period[57] - Financial expenses decreased by 61.27% compared to the beginning of the period, mainly due to an increase in interest income during the reporting period[57] Market Expansion - The company received orphan drug designation from the FDA for its product KH617, indicating potential for future market expansion[42]

Group 1: Company Overview - Kanghong Pharmaceutical is listed under stock code 002773 and is based in Chengdu, China [1] - The investor relations activity took place on April 28, 2017, with key executives present, including the Chairman and CEO [1][3] Group 2: Product Development and Research - The company is focusing on the consistency evaluation of generic drugs, specifically Aripiprazole orally disintegrating tablets, which have completed pharmaceutical research and submitted BE ethical review materials [3][4] - Ongoing clinical research preparations for KH704-R02 (Duloxetine Hydrochloride orally disintegrating tablets) and KH705-R01 (Esomeprazole Magnesium enteric-coated capsules) are in progress [5] - The company aims to develop high-end APIs and quality formulations, focusing on new molecules and formulations [4][6] Group 3: Innovation Strategy - The innovation strategy includes a combination of independent development and collaboration, focusing on core areas such as ophthalmology, central nervous system, digestive system, and oncology [5][6] - The company is also developing new traditional Chinese medicine products and expanding international cooperation for product globalization [6][9] Group 4: Market Expansion and Clinical Trials - KH906 has received clinical approval and is expected to address a significant market need for treating new blood vessel diseases post-injury and chemical burns [7][8] - The company plans to conduct large-sample clinical studies for Kangbaxip (康柏西普) from 2014 to 2019, covering over 5,000 subjects [8][9] Group 5: Regulatory and Market Challenges - The new medical insurance directory is expected to support innovative drugs and traditional Chinese medicine, enhancing their market presence [9][10] - The company is preparing for potential competition from foreign innovative drugs entering the Chinese market, with a robust intellectual property protection strategy in place [12][13] Group 6: Financial Outlook and Growth Potential - The introduction of Keluoxin capsules into the new medical insurance directory is anticipated to significantly boost sales, especially in the diabetic nephropathy market [10][11] - The company is actively seeking partnerships to expand its production capacity and meet future market demands [14]

Group 1: Company Performance - The company reported a net profit growth of 25.98% in 2016 compared to the previous year [6] - For 2017, the company expects revenue and net profit to grow by 12-22% and 15-28% respectively compared to 2016 [6] Group 2: Product and Market Insights - The market for diabetic retinopathy, a new indication for the drug Langmu, accounts for 40%-50% of eye diseases, indicating significant market potential [2] - The company has not conducted precise market capacity assessments for future products [2] Group 3: Financial Reporting and Costs - The company allocated over 80 million yuan for poverty alleviation efforts in 2016, which was recorded as non-operating expenses [2] - Management expenses for 2016 were reported to be over 80 million yuan, with a significant portion attributed to equity incentives [4] Group 4: Research and Development - The company is focused on ophthalmology as its core treatment area, ensuring that new drug development aligns with this focus [3] - The clinical trial for the drug Kangbai Xip in the U.S. is currently in progress, with the selection of a CRO and confirmation of clinical protocols ongoing [3] Group 5: Market Strategy and Competition - The company is committed to maintaining its market strategy and will adjust promotional expenses based on market conditions, especially if Langmu is included in the national medical insurance directory [4] - The impact of price reductions on the drug Leizhu single antibody is acknowledged, and the company is strategizing to mitigate these effects [5]

Financial Performance - The company forecasts a revenue and net profit growth of 0-10% for 2020 compared to 2019 [4] - The financial budget report was approved by the board on April 28, 2020, indicating internal management control indicators [4] Clinical Trials and Research - The global multi-center Phase III clinical trial for KHB-1801 is ongoing in over 300 clinical trial centers across more than 30 countries [5] - The trial aims to evaluate the efficacy and safety of KHB-1801 in treating patients with neovascular age-related macular degeneration (nAMD) [5] - A total of 1,140 subjects are planned to be recruited for the two independent but similar trials [5] - The main efficacy analysis will be conducted at week 36 post-treatment, with a total treatment duration of 92 weeks [5] Product Development and Approvals - KHB-1801 has received approval for a third indication: treatment of vision impairment due to diabetic macular edema (DME) [6] - The drug is already approved for two indications: wet age-related macular degeneration (nAMD) and myopic choroidal neovascularization (pmCNV) [6] - Clinical trials for retinal vein occlusion (RVO) are currently in Phase III in China [6] Patient Assistance Programs - The company, in collaboration with the China Social Relief Foundation, launched a patient assistance program that donated over 60 million yuan worth of KHB-1801 to low-income and impoverished patients in 2019 [7] - Over the past five years, the total assistance value has reached approximately 250 million yuan, benefiting over 40,000 individuals [7] Competitive Landscape - The main competition for KHB-1801 comes from other anti-VEGF drugs, with the latest guidelines recommending anti-VEGF drugs as the first-line treatment for RVO and DME [8] - The FDA approved RTH258 for wet AMD treatment in October 2019, which has a different administration schedule compared to KHB-1801 [8] - Ongoing studies are evaluating the safety and efficacy of various competing products, including dual-specificity antibody drugs [9]

Financial Performance - In Q1 2020, the company's revenue decreased by 11.76% compared to the same period last year, with net profit attributable to shareholders declining by 16.30% [4] - Revenue from biological products fell by approximately 35%, while traditional Chinese medicine revenue decreased by about 11.1%. Chemical drug revenue increased by approximately 8.8% [4] - The price of the eye injection drug, Kangbai Xip, dropped by about 25% after being included in the national medical insurance directory, contributing to the revenue decline [4] Clinical Research Progress - Kangbai Xip eye injection (brand name: Langmu) is currently in Phase III clinical trials for three indications: wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (pmCNV), and diabetic macular edema (DME) [5] - The global multi-center Phase III clinical trial involves over 300 clinical trial centers across more than 30 countries, aiming to evaluate the drug's efficacy and safety [5] - The trials are expected to recruit a total of 1,140 participants, with the main efficacy analysis scheduled for week 36 post-treatment [5] Market Strategy and Commercialization - The overseas commercialization of Kangbai Xip is a key focus, with plans to adapt marketing strategies based on specific country requirements as clinical trials progress [6] - The product has gained significant market share since its launch in 2014, and by 2018, it was leading in market share compared to competitors [8] - The company aims to enhance the treatment capabilities of grassroots hospitals through training and educational initiatives [8] Research and Development - The company is committed to increasing investment in research and development, with R&D expenditure accounting for 24.18% of revenue in 2019 and expected to be around 15% in 2020 [9] - Continuous adjustments and recruitment of international talent are being made to strengthen the R&D team [9]

Sales Performance - In Q1 2020, the revenue from biological products decreased by approximately 35% compared to the same period last year, while traditional Chinese medicine revenue fell by about 11.1%, and chemical drugs increased by approximately 8.8% [4] - The decline in revenue for the drug Conbercept was attributed to the COVID-19 pandemic, which led to a significant drop in patient visits due to the closure of ophthalmology clinics [4] - As of April 2020, the injection numbers for Conbercept increased by over 100% compared to March [4] Clinical Trials - The global Phase III clinical trials for Conbercept are being conducted in over 30 countries with 300 clinical trial centers, aiming to recruit 1,140 subjects for each of the two independent trials [5] - The trials are designed to evaluate the efficacy and safety of Conbercept for treating neovascular age-related macular degeneration [5] - Despite the pandemic, the clinical trials are proceeding as planned, with measures in place to ensure participant safety [6] Research and Development - In 2019, R&D investment accounted for 24.18% of revenue, with an expected decrease to around 15% in 2020, but anticipated to maintain or grow in the coming years [7] - The company is focusing on enhancing its product pipeline in core therapeutic areas such as ophthalmology and neurology, with ongoing research for various drugs [7][8] - The company has introduced new drugs for conditions like Alzheimer's disease and is advancing multiple products through clinical trials [8] Market Strategy - The company has adjusted its sales strategy in response to new industry policies, achieving a recovery in traditional Chinese medicine sales by the end of 2019 [9] - The company’s products, including Conbercept, have demonstrated significant economic advantages and efficacy, positioning them well in the market [11] - The company is committed to improving treatment access in grassroots hospitals through educational initiatives and training programs for healthcare professionals [11]